Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors

scientific article published on 25 February 2019

Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1078-0432.CCR-18-3997
P932PMC publication ID7159438
P698PubMed publication ID30804020

P50authorTanios Bekaii-SaabQ43376169
P2093author name stringLai Wei
Amir Mortazavi
Robert Wesolowski
Christina Wu
Pravin T P Kaumaya
Bhuvaneswari Ramaswamy
Maryam Lustberg
Daniel H Ahn
Jeffrey Fowler
Jay Overholser
P433issue12
P921main subjectimmunologic adjuvantQ967453
immunotherapyQ1427096
phase I clinical trialQ5452194
P304page(s)3495-3507
P577publication date2019-02-25
P1433published inClinical Cancer ResearchQ332253
P1476titlePhase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
P478volume25

Reverse relations

cites work (P2860)
Q94596514A Multiple Antigen Peptide Vaccine Containing CD4+ T Cell Epitopes Enhances Humoral Immunity against Trichinella spiralis Infection in Mice
Q90699157Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment
Q91719970Peptide-Based Vaccines: Current Progress and Future Challenges
Q100526249Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen

Search more.